BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36877451)

  • 21. Surveillance for isocyanate asthma: a model based cost effectiveness analysis.
    Wild DM; Redlich CA; Paltiel AD
    Occup Environ Med; 2005 Nov; 62(11):743-9. PubMed ID: 16234399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding quality-adjusted life years and their application to pharmacoeconomic research.
    Raisch DW
    Ann Pharmacother; 2000; 34(7-8):906-14. PubMed ID: 10928403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
    Russell LB; Gold MR; Siegel JE; Daniels N; Weinstein MC
    JAMA; 1996 Oct; 276(14):1172-7. PubMed ID: 8827972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel.
    Brouwer WB; Koopmanschap MA; Rutten FF
    Int J Technol Assess Health Care; 1998; 14(3):505-13. PubMed ID: 9780537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis.
    Basu A; Carlson J; Veenstra D
    Value Health; 2020 Jan; 23(1):96-103. PubMed ID: 31952678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis.
    Mattingly TJ; Slejko JF; Onukwugha E; Perfetto EM; Kottilil S; Mullins CD
    Pharmacoeconomics; 2020 Feb; 38(2):233-242. PubMed ID: 31788751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
    Shah D; Lu X; Paly VF; Tsintzos SI; May DM
    J Med Econ; 2020 Jul; 23(7):690-697. PubMed ID: 32207659
    [No Abstract]   [Full Text] [Related]  

  • 29. Costs and benefits of carotid endarterectomy and associated preoperative arterial imaging: a systematic review of health economic literature.
    Benade MM; Warlow CP
    Stroke; 2002 Feb; 33(2):629-38. PubMed ID: 11823682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
    Gazzard G; Konstantakopoulou E; Garway-Heath D; Garg A; Vickerstaff V; Hunter R; Ambler G; Bunce C; Wormald R; Nathwani N; Barton K; Rubin G; Morris S; Buszewicz M
    Health Technol Assess; 2019 Jun; 23(31):1-102. PubMed ID: 31264958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
    Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
    J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years.
    Robertson W; Fleming J; Kamal A; Hamborg T; Khan KA; Griffiths F; Stewart-Brown S; Stallard N; Petrou S; Simkiss D; Harrison E; Kim SW; Thorogood M
    Health Technol Assess; 2017 Jan; 21(1):1-180. PubMed ID: 28059054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
    Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
    J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness.
    Pickett K; Loveman E; Kalita N; Frampton GK; Jones J
    Health Technol Assess; 2015 Oct; 19(86):1-176, v-vi. PubMed ID: 26502807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
    Culyer AJ; Chalkidou K
    Value Health; 2019 Jan; 22(1):99-103. PubMed ID: 30661640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.
    Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J
    Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of MammaPrint
    Luyendijk M; Jager A; Buijs SM; Siesling S; Groot CAU; Blommestein HM
    Pharmacoeconomics; 2023 Aug; 41(8):981-997. PubMed ID: 37245167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.
    Luciano JV; D'Amico F; Cerdà-Lafont M; Peñarrubia-María MT; Knapp M; Cuesta-Vargas AI; Serrano-Blanco A; García-Campayo J
    Arthritis Res Ther; 2014 Oct; 16(5):451. PubMed ID: 25270426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.
    Yuasa A; Yonemoto N; Kamei K; Murofushi T; LoPresti M; Taneja A; Horgan J; Ikeda S
    Adv Ther; 2022 Dec; 39(12):5327-5350. PubMed ID: 36205907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.